DDIT3 is altered in 54.0% of myxoid liposarcoma patients [2].

DDIT3 is an inclusion eligibility criterion in 2 clinical trials for myxoid liposarcoma, of which 2 are open and 0 are closed. Of the trials that contain DDIT3 status and myxoid liposarcoma as inclusion criteria, 2 are phase 2 (2 open) [3].

EWSR1 is altered in 2.9% of myxoid liposarcoma patients [2].

EWSR1 is an inclusion eligibility criterion in 1 clinical trial for myxoid liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains EWSR1 status and myxoid liposarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FUS is altered in 41.67% of myxoid liposarcoma patients [2].

FUS is an inclusion eligibility criterion in 3 clinical trials for myxoid liposarcoma, of which 3 are open and 0 are closed. Of the trials that contain FUS status and myxoid liposarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

PIK3CA is altered in 28.17% of myxoid liposarcoma patients [2].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for myxoid liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and myxoid liposarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PTEN is altered in 16.9% of myxoid liposarcoma patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for myxoid liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and myxoid liposarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TAF15 is an inclusion eligibility criterion in 1 clinical trial for myxoid liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains TAF15 status and myxoid liposarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].